Quick Answer
Janux Therapeutics, Inc. reported Research And Development Expense of $125.90 million for the year ending 2025.
- Janux Therapeutics, Inc. showed an increase of +84.1% in Research And Development Expense from 2024 to 2025.
- This data is from Janux Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $673.0 thousand | Q3 2020: $834.0 thousand | Q1 2021: $1.93 million | Q2 2021: $4.74 million | Q3 2021: $8.41 million | Q1 2022: $10.18 million | Q2 2022: $14.09 million | Q3 2022: $13.74 million | Q1 2023: $15.87 million | Q2 2023: $14.92 million | Q3 2023: $11.89 million | Q1 2024: $14.07 million | Q2 2024: $14.90 million | Q3 2024: $18.61 million | Q1 2025: $25.06 million | Q2 2025: $34.66 million | Q3 2025: $34.63 million.
- Over the full 6 years of available data (2020 to 2025), Janux Therapeutics, Inc.'s Research And Development Expense has grown by 4,040.0%.
- Historical annual values: Fiscal year 2025: $125.90 million | Fiscal year 2024: $68.39 million | Fiscal year 2023: $54.92 million | Fiscal year 2022: $53.44 million | Fiscal year 2021: $26.24 million | Fiscal year 2020: $3.04 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: